KedRAB FDA Approval History
FDA Approved: Yes (First approved August 23, 2017)
Brand name: KedRAB
Generic name: rabies immunoglobulin human
Dosage form: Injection
Company: Kamada Ltd. and Kedrion S.p.A.
Treatment for: Rabies Prophylaxis
KedRAB [rabies immunoglobulin (human)] is a human plasma derived anti-rabies immunoglobulin indicated for post-exposure prophylaxis (PEP) of rabies infection.
Development Timeline for KedRAB
|Aug 25, 2017||FDA Approves KedRAB [rabies immune globulin (Human)] for Post-Exposure Prophylaxis of Rabies Infection|
|Sep 1, 2016||Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.